New findings show Alcon AcrySof® platform has lower complications post-surgery, with PanOptix® improving refractive outcomes for cataract patients
Sep 22, 2018
Five-year data demonstrate the real-world value of AcrySof® IOLs in reducing posterior capsule opacification (PCO) after cataract surgery1,2
PanOptix® trifocal IOLs significantly improve near, intermediate and distance visual acuity at 12-months post-surgery3 and show better visual outcomes at 6 months vs. competitor4
Detailed findings to be presented at the 36th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS)
Vienna, Saturday, September 22, 2018 – Alcon, the global leader in eye care and a division of Novartis, will present new data highlighting the benefits of AcrySof® IQ intraocular lenses (IOLs) at the 36th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) taking place September 22-26 in Vienna, Austria. Presentations will include data across lenses in the market-leading AcrySof® platform, including the AcrySof® IQ monofocal IOL and AcrySof® IQ PanOptix® trifocal IOL, Alcon’s latest trifocal lens designed to deliver clear vision at near, intermediate and far distances and reduce dependence on spectacles after cataract surgery.
“We’re proud that Alcon AcrySof® IQ IOLs continue to demonstrate the reliability that surgeons and patients have come to expect from our portfolio of best-in-class products,” said Dr. Stephen Lane, MD, Chief Medical Officer (CMO) and Global Head Franchise Clinical Strategy at Alcon. “These findings further reinforce the strength of the AcrySof® platform and underscore the value that our next-generation AcrySof® IQ PanOptix® IOLs provide to patients.”
Findings of new studies that demonstrate the performance of AcrySof® IQ PanOptix® post-surgery and real-world evidence for Alcon AcrySof® IQ monofocal IOLs will be shared during presentations at the ESCRS meeting:
Alcon AcrySof® IQ PanOptix® trifocal IOLs significantly improved visual acuity at 12-months post-surgery in corrected, uncorrected conditions across a range of distances.3
A new study, “Multicenter visual outcomes evaluation of a novel trifocal presbyopia-correcting intraocular lens: 12 months postoperative results” evaluated the Visual Acuity and Binocular Defocus Curve outcomes of the AcrySof® IQ PanOptix® trifocal IOL. Results from the analysis of 151 patients demonstrated that patients implanted with the AcrySof® IQ PanOptix® trifocal IOL showed visual acuity of 20/25 or better in both corrected and uncorrected conditions across near, intermediate and distance visions.3 Results will be presented by Prof. Thomas Kohnen, on Sunday, September 23 at 4:36pm CEST in Room A3, Podium 1.
“These robust data show that the PanOptix® trifocal lens enabled patients to achieve excellent results in visual acuity, especially at an intermediate distance of 60cm,” said Thomas Kohnen, MD, PhD, FEBO, Chair of the Department of Ophthalmology Goethe University, Frankfurt and lead study author. “PanOptix® proves to be a valuable option for those looking for less dependence on spectacles in their everyday life.”
Multicenter clinical investigation of visual function after bilateral implantation of two presbyopia-correcting trifocal IOLs4
This prospective, multi-center, randomized, double-masked, parallel group post-market clinical study involved bilateral implantations and followed 182 patients for six months. The study was designed to clinically qualify bench studies and model predictions of the visual performance of AcrySof® IQ PanOptix® and the AT LISA* tri 839MP Presbyopia-Correcting IOL. Results showed the AcrySof® IQ PanOptix® group had superior visual outcomes at six months in uncorrected intermediate visual acuity at 60 cm (p<0.002) and uncorrected near visual acuity at 40 cm (p<0.003). In addition, the study showed that AcrySof® IQ PanOptix® was non-inferior in uncorrected distance visual acuity (95 percent SCI <0.1 logMAR). Findings demonstrated that both IOLs improved visual acuity while AcrySof® IQ PanOptix® IOLs provided better near and intermediate vision compared to the ZEISS AT LISA* tri 839MP IOL.4 Results will be presented by Dr. Ruth Lapid-Gortzak on Saturday, September 22, 3:45pm CEST in the Poster Village: Pod 1.
*AT LISA is a registered trademark owned by or licensed to ZEISS.
Patients implanted with Alcon AcrySof® Monofocal IOLs had significantly lower rates of a common complication after cataract surgery compared to those implanted with comparable IOLs on the market.1,2
Findings from “Incidence of Nd:YAG capsulotomy following single-piece monofocal acrylic IOL implantation: a retrospective real world evidence study in the UK” demonstrate that cataract patients implanted with an AcrySof® monofocal IOL are less likely to develop posterior capsule opacification (PCO) or to require a Nd:YAG laser procedure to correct PCO after cataract surgery, than those implanted with other monofocal hydrophilic or hydrophobic IOLs currently available to patients.1 PCO, often called the “secondary cataract,” is the most frequent long-term complication following cataract surgery.5 The study retrospectively analyzed 47,754 and 20,763 eyes over three and five years, respectively, generating robust long-term data that show the value of Alcon IOLs in the real-world setting.1,2 The five-year results will be shared during a poster presentation on Monday, September 24, at 3:30pm CEST in the Poster Village: Pod 1. These results confirmed the three-year analysis recently published in the June 2018 journal issue of Eye.2
About AcrySof® IQ PanOptix® and monofocal IOLs
As with any surgical procedure, there are associated risks. Potential complications accompanying cataract surgery include corneal endothelial damage, endophthalmitis, retinal detachment, vitritis, cystoid macular edema, corneal edema, pupillary block, cyclitic membrane, iris prolapse, hypopyon, and transient or persistent glaucoma. Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the physician labeling.
Side effects associated with multifocal IOLs include visual disturbances such as glare, rings around lights and blurred vision. These side effects might make it more difficult to see while driving at night or completing tasks in low lighting such as at night or in fog, after surgery as compared to before surgery. Posterior capsule opacification (PCO) may significantly affect the vision of patients with multifocal IOLs sooner in its progression than in patients with monofocal IOLs.
Alcon is the global leader in eye care. As a division of Novartis, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our products touch the lives of more than 260 million people each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors, and there are millions more who are waiting for solutions to meet their eye care needs. Our purpose is reimagining eye care, and we do this through innovative products, partnerships with eye care professionals and programs that enhance access to quality eye care. Learn more at www.alcon.com.
Dhariwal M, et al. Incidence of Nd:YAG capsulotomy following single-piece monofocal acrylic IOLs implantation: a retrospective real world evidence study in the UK. XXXVI Congress of the ESCRS. Vienna 2018.
Ursell P, Dhariwal M, Three-year incidence of Nd:YAG capsulotomy and posterior capsule opacification and its relationship to monofocal acrylic IOL biomaterial: a UK Real World Evidence study. Eye (Lond) 2018 June 11(accepted May 3 2018; Paper #EYE-18-171)
Kohnen T, Martinez A. Multicenter Visual Outcomes Evaluation of a Novel Trifocal Presbyopia Correcting IOL – 12 months post-op results. XXXVI Congress of the ESCRS. Vienna 2018.
Lapid-Gortzak R, Multicenter Visual Outcomes comparison of two Trifocal Presbyopia Correcting IOLs – 6 months post-op results. XXXVI Congress of the ESCRS. Vienna 2018.